ASAlberto Severini

Alberto Severini

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alberto Severini has a total of 176 co-authors. Here are the top co-authors by number of shared publications:

  • Joanne Hiebert

    Measles, mumps and rubella Section, National Microbiology Laboratory, Public Health Agency of Canada, JC Wilt infectious Diseases Research Centre, 745 Logan Avenue, Winnipeg, Manitoba, Postal Code R3E 3L5, Canada

    12 shared publications
  • Elizabeth McLachlan

    National Microbiology Laboratory Branch, Public Health Agency of Canada, Winnipeg, MB R3E 3R2, Canada

    5 shared publications
  • Vanessa Zubach

    Viral Exanthemata and STD Section, National Microbiology Laboratory, Public Health Agency of Canada , Winnipeg, Manitoba, Canada

    5 shared publications
  • Jasmine Rae Frost

    Department of Medical Microbiology and Infectious Diseases, Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada

    4 shared publications
  • Vanessa Zubach

    Measles, mumps and rubella Section, National Microbiology Laboratory, Public Health Agency of Canada, JC Wilt infectious Diseases Research Centre, 745 Logan Avenue, Winnipeg, Manitoba, Postal Code R3E 3L5, Canada

    4 shared publications
  • Helene Schulz

    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada

    3 shared publications

Latest Publications

  • Open Access

    Assessing measles immunity in individuals of childbearing age in Toronto, Ontario, Canada

    by Selma Osman, Elizabeth McLachlan, Alberto Severini, Callum Arnold, Dara Petel, Todd Hatchette, Shelley Deeks, Scott A. Halperin, James Wright, Kevin Brown, et al.


  • Prevalence, Treatment, and Follow-Up for Lymphogranuloma Venereum Serovars of Chlamydia trachomatis Among Gay, Bisexual, and Other Men Who Have Sex With Men Attending Sexually Transmitted Infection Clinics in Alberta, Canada, 2018 to 2022

    by Jennifer Gratrix, Sabrina Plitt, John Niruban, Jennifer Karwacki, Emily McCullough, Caley B. Shukalek, Angel Chu, Suzanne Gibbons, Alberto Severini, Petra Smyczek

    Background: Outbreaks of lymphogranuloma venereum (LGV) have been reported among gay, bisexual, and men who have sex with other men (gbMSM) in Europe and North America. In Alberta, Canada, a universal surveillance program was initiated to assess LGV rates among gbMSM seen at provincial sexually transmitted infection clinics. Our study examines the epidemiological characteristics and treatment of cases. Methods: We describe a prospective, multicenter LGV surveillance program using chlamydia-positive nucleic acid amplification test specimens from gbMSM collected at 3 sexually transmitted infection clinics between April 2018 and July 2022. Chlamydia-positive specimens from rectal, pharyngeal, and urine specimens were sent for LGV typing. Treatment and test of cure for LGV-confirmed cases were followed. Demographic variables were compared between LGV-positive and LGV-negative specimens using χ 2 tests for categorical variables and Mann-Whitney U tests for continuous variables. Results: Eighty-five percent (n = 2333) of all chlamydia-positive specimens were tested for LGV, and 45 (1.9%; 95% confidence interval, 1.4%–2.5%) specimens were confirmed to be LGV. A majority (n = 1374) of specimens submitted for LGV testing were rectal swabs, of which 37 (2.7%) were positive. One-half (51.2% [22 of 43]) of cases were asymptomatic. Of the 22 cases with a negative test-of-cure result, 9 (40.9%) patients received doxycycline 100 mg twice a day for 21 days, 7 (31.8%) patients received azithromycin 1 g as a single dose, 5 (22.7%) patients received doxycycline 100 mg twice a day for 7 days, and 1 patient (4.6%) was treated with doxycycline 100 mg twice a day for 14 days. Conclusions: Universal testing increased the detection of LGV among asymptomatic patients. Future research should consider the impact of asymptomatic LGV in transmission networks and the role of alternate, shorter treatment regimens than the recommended 21 days of doxycycline.


  • Open Access

    Surveillance for Chlamydia trachomatis variants escaping detection with the Aptima Combo 2 assay in Canada from 2019 to 2021

    by Felicia Roy, Jennifer Beirnes, Jason J. LeBlanc, Suzanne Gibbons, Aida Sivro, Alberto Severini, On behalf of the Canadian Public Health Laboratory Network (CPHLN) Chlamydia Variant Working Group

    Nucleic acid amplification tests (NAATs) are the method of choice for Chlamydia trachomatis diagnosis, but these strategies are susceptible to target site mutations. C. trachomatis variants escaping detection with the Aptima Combo 2 (AC2) assay on the Hologic Panther instrument from 23S rRNA mutations have been reported in Nordic countries, England, Japan, and the United States. Given the potential for false negative results, this study investigated whether strains of C. trachomatis with AC2 target site mutations were present in Canada. Surveillance was conducted in Canadian laboratories from 2019 to 2021. Specimens suspected of AC2 target site mutations included those with low-value detections on the AC2 assay, with subsequent high-value detections on the Aptima Chlamydia Trachomatis (ACT) assay used for confirmatory testing. Specimens with AC2/ACT discrepant results were subjected to sequencing of the AC2 target (i.e., 23S rRNA). Sequencing revealed 15 (4.8%) diagnostic escape variants which were carrying either C1514T, G1523A, or G1526A mutations. All specimens with a diagnostic escape mutation were detected with a reformulated version of the AC2 assay. Overall, while the prevalence of C. trachomatis variants was rare, their presence in the Canadian population supports the use of the new AC2 kit formulation and the need for ongoing genetic surveillance for NAAT-based assays. IMPORTANCE: Molecular tests are commonly used for the detection of sexually transmitted infections (STIs) like Chlamydia trachomatis . Mutations impacting C. trachomatis molecular target detection on the Hologic Panther AC2 assay have been reported in several countries, raising concerns about potential false negative results. This study showed C. trachomatis target detection failures in specimens submitted for C. trachomatis testing in Canadian laboratories from 2019 to 2021. A reformulated version of the AC2 molecular test is now available that can identify C. trachomatis strains harboring target site mutations that were impacted by the previous test formulation. While target site mutations were rare in Canada, revealing their presence is important to ensure accurate molecular detection of C. trachomatis with existing testing methods. This study supports ongoing genetic monitoring of C. trachomatis molecular test target sites, as well as the use of the reformulated test to avoid false negative results and subsequent transmissions.


  • Open Access

    Serologic Cross-Reactivity between the Mumps Virus Vaccine Genotype A Strain and the Circulating Genotype G Strain

    by Sabaparvin Shaikh, Michael Carpenter, Lisa Lin, Jasmine Rae Frost, Elizabeth McLachlan, Derek Stein, Paul Van Caeseele, Alberto Severini

    Recent mumps outbreaks have been observed in vaccinated young adults due to the mumps virus (MuV) of genotype G, whereas the current vaccine is a mixture of two genotype A strains. These outbreaks could be attributed to waning vaccine immunity or the antigenic differences between the HN and F glycoproteins in the vaccine and circulating MuV. These glycoproteins are essential targets for the immune system, and antigenic variations may reduce the recognition of mumps antibodies, rendering the population susceptible to the MuV. We established stable cell lines expressing the MuV glycoproteins to study cross-reactivity between genotype A and genotype G. Cross-reactivity between the genotypes was evaluated via immunofluorescence using patient sera from vaccinated individuals, infected individuals, and vaccinated individuals infected with genotype G. Titer ratios showed that the vaccinated individuals exhibited a titer 3.68 times higher for the HN protein and 2.3 times higher for the F protein when comparing genotype A with genotype G. In contrast, the infected individuals showed a lower titer for genotype A compared with genotype G, at 0.43 and 0.33 for the HN and F proteins, respectively. No difference in titer ratio was observed for individuals vaccinated and subsequently infected with mumps. These findings suggest that antigenic variations between the two genotypes may potentially result in immune escape of the circulating strain, resulting in individuals susceptible to the MuV.


  • Open Access

    Genomic Characterization of Three Canadian Mumps Outbreaks Demonstrates Endemic Transmission in Canada

    by Jasmine Rae Frost, Grace Eunchong Seo, Kerry Dust, Jared Bullard, Peter Daley, Jason J. LeBlanc, Joanne Hiebert, Elizabeth McLachlan, Alberto Severini

    Despite the provision of a mumps vaccination program in Canada for over three decades, mumps has not reached elimination. Instead, a re-emergence has been observed in vaccinated populations, particularly in young adults. These outbreaks have been almost exclusively due to genotype G infections, a trend that has been seen in other countries with high mumps vaccination rates. To characterize mumps outbreaks in Canada, genomes from samples from Manitoba (n = 209), Newfoundland (n = 25), and Nova Scotia (n = 48) were sequenced and analysed by Bayesian inference. Whole genome sequencing was shown to be highly discriminatory for outbreak investigations compared to traditional Sanger sequencing. The results showed that mumps virus genotype G most likely circulated endemically in Canada and between Canada and the US. Overall, this Canadian outbreak data from different provinces and ancestral strains demonstrates the benefits of molecular genomic data to better characterize mumps outbreaks, but also suggests genomics could further our understanding of the reasons for potential immune escape of mumps genotype G and evolution in highly vaccinated populations. With a possible endemic circulation of mumps genotype G and the remaining risk of new imported cases, increased surveillance and alternative vaccination strategies may be required for Canada to reach the current target for mumps or a future elimination status.


  • Open Access

    Diagnostic accuracy of commercially available serological tests for the detection of measles and rubella viruses: a systematic review and meta-analysis

    by Vanessa Zubach, Jennifer Beirnes, Shannon Hayes, Alberto Severini, Joanne Hiebert

    Measles and rubella serological diagnoses are done by IgM detection. The World Health Organization Global Measles and Rubella Laboratory Network previously endorsed Siemens Enzygnost enzyme-linked immunosorbant assay kits, which have been discontinued. A recommended replacement has not been determined. We aimed to search for suitable replacements by conducting a systematic review and meta-analysis of IgM detection methods that are currently available for measles and rubella. A systematic literature search was performed in Medline, Embase, Global Health, Cochrane Central, and Scopus on March 22 and on 27 September 2023. Studies reporting measles and/or rubella IgM detection with terms around diagnostic accuracy were included. Risk of bias was assessed using QUADAS tools. Meta-DiSc and R were used for statistical analysis. Clinical samples totalling 5,579 from 28 index tests were included in the measles meta-analysis. Sensitivity and specificity of the individual measles studies ranged from 0.50 to 1.00 and 0.53 to 1.00, respectively. Pooled sensitivity and specificity of all measles IgM detection methods were 0.94 (CI: 0.90-0.97) and 0.94 (CI: 0.91-0.97), respectively. Clinical samples totalling 4,983 from 15 index tests were included in the rubella meta-analysis. Sensitivity and specificity of the individual rubella studies ranged from 0.78 to 1.00 and 0.52 to 1.00, respectively. Pooled sensitivity and specificity of all rubella IgM detection methods were 0.97 (CI: 0.93-0.98) and 0.96 (CI: 0.93-0.98), respectively. Although more studies would be ideal, our results may provide valuable information when selecting IgM detection methods for measles and/or rubella.


  • Open Access

    Genome sequence of a measles virus strain with a novel loss of stop codon mutation in the phosphoprotein gene

    by Vanessa Zubach, Helene Schulz, Kihun Kim, Darian Hole, Alberto Severini, Joanne Hiebert

    Measles virus genotype B3 coding-complete genome sequence from a 2019 case showed a novel mutation in the phosphoprotein (P) gene that abrogates the established stop codon. A downstream stop codon has been identified, resulting in a putative P that would be 19 amino acids longer than wild type.


  • Open Access

    Dimeric immunoglobulin A as a novel diagnostic marker of measles infection

    by Khayriyyah Mohd Hanafiah, Joanne Hiebert, Vanessa Zubach, Alberto Severini, David A. Anderson, Heidi E. Drummer

    Despite tremendous measles incidence reduction through universal vaccination, elimination efforts rely on improved surveillance. The detection of anti-measles immunoglobulin M (IgM) by enzyme-linked immunosorbent assay is the standard laboratory diagnostic method. However, true infection is rare, and seroconversion following measles, mumps, and rubella vaccination also generates IgM, which results in low positive predictive values of assays in elimination settings, thus necessitating confirmatory testing. Improved diagnostic tests for measles infection are a World Health Organization research priority. We investigated whether dimeric immunoglobulin A (dIgA), the predominant antibody produced in mucosal immunity, may be a marker of recent or acute measles infection. We examined a serological panel of confirmed measles infection (anti-measles IgM positives, n = 50) and non-measles infection with rubella ( n = 36), roseola ( n = 40), chikungunya/dengue/zika ( n = 41), parvovirus ( n = 35), and other fever-rash illnesses of unknown cause ( n = 37). Sera were examined on microimmune anti-measles IgM, Euroimmun anti-measles virus lysate (VL), and nucleoprotein (NP) IgM kits. Assays were then modified to detect dIgA using an in-house protocol based on a recombinant chimeric secretory component protein and an anti-secretory component monoclonal antibody. We observed significantly higher levels of anti-measles VL dIgA in measles samples than in non-measles controls ( P < 0.001), and there was a low correlation with IgM (R 2 : 0.01, P value: 0.487). Unlike IgM, dIgA reactive to measles NP was not detected in most samples. The comparable diagnostic potential of anti-measles dIgA (area under the curve, AUC: 0.920–0.945) to anti-measles IgM (AUC: 0.986–0.995) suggests that dIgA may be a new blood-based marker of acute measles, independent of IgM, which merits further investigation and optimization. IMPORTANCE: The world is facing a measles resurgence, and improved diagnostic tests for measles infection are an urgent World Health Organization research priority. Detection of measles-specific immunoglobulin M (IgM) as a standard diagnostic test has low positive predictive value in elimination settings, and there is a need for new biomarkers of measles infection to enable enhanced surveillance and response to outbreaks. We demonstrate the detection of measles-specific dimeric immunoglobulin A (dIgA) in patients with confirmed measles infections using a new indirect enzyme-linked immunosorbent assay protocol that selects for the dIgA fraction from total IgA in the blood. The magnitude of measles-specific dIgA responses showed a low correlation with IgM responses, and our results highlight the potential of dIgA for further development as an alternative and/or complementary biomarker to IgM for serological diagnosis of measles infection.


  • Open Access

    Dimeric immunoglobulin A as a novel diagnostic marker of measles infection

    by Khayriyyah Mohd Hanafiah, Joanne Hiebert, Vanessa Zubach, Alberto Severini, David A. Anderson, Heidi E. Drummer

    Despite tremendous measles incidence reduction through universal vaccination, elimination efforts rely on improved surveillance. Detection of anti-measles immunoglobulin M (IgM) by ELISA is the standard laboratory diagnostic method. However, true infection is rare and seroconversion following MMR vaccination also generates IgM, which results in low positive predictive values of assays in elimination settings, thus necessitating confirmatory testing. Improved diagnostic tests for measles infection are a World Health Organization (WHO) research priority. We investigated whether dimeric immunoglobulin A (dIgA), the predominant antibody produced in mucosal immunity, may be a marker of recent or acute measles infection. We examined a serological panel of confirmed measles infection (anti-measles IgM positives, n=50), and non-measles infection with rubella (n=36), roseola (n=40), chikungunya/dengue/zika (n=41), parvovirus (n=35) and other fever-rash illness of unknown cause (n=37). Sera were examined on a Micrommune anti-measles IgM, Euroimmun anti-measles virus lysate (VL) and nucleoprotein (NP) IgM kits. Assays were then modified to detect dIgA using an in-house protocol based on a recombinant chimeric secretory component protein and anti-secretory component monoclonal antibody. We observed significantly higher levels of anti-measles VL dIgA in measles samples than non-measles controls (p2 : 0.01, p value:0.487). Unlike IgM, dIgA reactive to measles NP was not detected in most samples. Comparable diagnostic potential of anti-measles dIgA (AUC 0.920 - 0.945) to anti-measles IgM (AUC 0.986 – 0.995), suggests that dIgA may be a new blood-based marker of acute measles, independent of IgM, which merits further investigation and optimization.

  • Open Access

    Mumps resurgence in a highly vaccinated population: Insights gained from surveillance in Canada, 2002–2020

    by Joanne Hiebert, Myriam Saboui, Jasmine Rae Frost, Vanessa Zubach, Meghan Laverty, Alberto Severini